Tag Archive for: radioligand therapy

Astatine-211 PSMA-5: Scalable Alpha Therapy for Refractory Prostate Cancer

/in , , /by

211AtPSMA-5 emerges as a promising targeted alpha therapy for metastatic castration-resistant prostate cancer, particularly in patients who have exhausted standard treatments like androgen receptor pathway inhibitors, docetaxel, and cabazitaxel. This approach leverages astatine-211, a cyclotron-produced alpha emitter generated by bombarding abundant bismuth targets with alpha beams. The compound’s design mirrors established PSMA ligands such as […]

Read more

²²⁵Ac‑RAX104: A Next‑Generation PSMA Alpha Radioligand for Advanced Prostate Cancer

/in /by

RAX104 is a small molecule ligand designed specifically to target PSMA, the protein that is highly expressed on the surface of prostate cancer cells. When labeled with ²²⁵Ac, it forms a radioligand that combines the physical advantages of actinium‑225 (high linear energy transfer and a 10‑day half‑life) with a ligand engineered for better tumor retention. […]

Read more

UPLIFT Trial: Abemaciclib Safely Boosts PSMA for Better Radioligand Therapy in Advanced Prostate Cancer

/in , , , /by

The UPLIFT trial is a phase 1/2 study testing a new combo for metastatic castrate-resistant prostate cancer. Researchers at the University of California, San Francisco, designed this trial to boost the power of 177Lu-PSMA-617, a targeted radiation drug called a radioligand therapy. That drug latches onto PSMA, a protein stamped all over prostate cancer cells, […]

Read more

Phase 1 PAnTHa Trial: mCRPC First Data

/in , , /by

²²⁵Ac‑PSMA‑Trillium (BAY3563254) is an experimental treatment that delivers targeted alpha radiation to prostate cancer cells. It combines a highly selective PSMA‑binding molecule with an albumin‑binding domain that helps it stay in the bloodstream longer and reach tumors more effectively. The radioactive component, actinium‑225, is attached using a stable Macropa chelator to increase safety and stability. […]

Read more

ANDROMEDA Trial: Alpha vs. Beta PSMA Therapy

/in , , /by

The ANDROMEDA phase 2 trial represents an advancement in managing recurrent oligometastatic prostate cancer by directly pitting alpha-emitting 225Ac-PSMA-617 against the established beta-emitting 177Lu-PSMA-617 (Pluvicto), both combined with stereotactic body radiotherapy (SBRT). This head-to-head comparison stems from the need to address limitations in current therapies for patients whose cancer returns in 1-5 detectable spots on […]

Read more

Actinium‑225 NTSR1‑Targeted Radiopharmaceutical SKL35501

/in , , /by

SKL35501 is an emerging radiopharmaceutical therapy that embodies much of what “next‑generation oncology” is supposed to mean: precise targeting, potent cell kill, and a built‑in companion diagnostic strategy. In January 2026, the US FDA cleared SKL35501 and its imaging partner SKL35502 for a phase 1 Investigational New Drug (IND). SKL35501 originated as FL‑091, a small‑molecule […]

Read more

UPDATE: SECuRE Trial Phase 2 Shows 67% PSA50 Response in Heavily Pre-Treated mCRPC

/in , , /by

The latest interim update from the SECuRE trial reinforces the impression that copper‑67 PSMA targeting is emerging as a credible contender in the mCRPC radioligand space, with consistent PSA responses and a clean safety profile in a small but challenging population. The Safety Review Committee has endorsed continuation of the Phase 2 cohort expansion without […]

Read more

PSMA-1-DOTA: A New Ligand to Make Prostate Cancer Radioligand Therapy More Targeted

/in , /by

PSMA-targeted radioligand therapy (RLT) has transformed treatment for end-stage prostate cancer, offering strong tumor control in patients who have exhausted other options. However, these therapies frequently cause severe salivary gland damage, leading to debilitating dry mouth that often forces patients to stop treatment early. To overcome this, researchers at Case Western Reserve University developed PSMA-1-DOTA, […]

Read more

HRS-4357, a Novel PSMA-targeted Radiologand Therapy Phase 3 Trial

/in , , /by

HRS-4357, a novel PSMA-targeted radiopharmaceutical, is poised to enter a landmark Phase III clinical trial targeting metastatic castration-resistant prostate cancer (mCRPC). The trial, received approval from China’s National Medical Products Administration on December 23, 2025, and plans to enroll 370 patients across multiple centers in China. This randomized, open-label, controlled study will directly compare HRS-4357 […]

Read more

ADVC001: Lead-212 PSMA Alpha Therapy Shows Safety and Efficacy in mCRPC Trial

/in , , /by

At the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, new clinical data from a Phase 1b dose escalation trial investigating ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) was presented. The therapy utilizes a radioactive isotope, Lead-212, to deliver targeted alpha radiation to prostate cancer cells, aiming […]

Read more